• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.抗 CD26 单克隆抗体抑制中东呼吸综合征冠状病毒感染。
J Virol. 2013 Dec;87(24):13892-9. doi: 10.1128/JVI.02448-13. Epub 2013 Sep 25.
2
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.一种构象依赖性中和单克隆抗体，特异性靶向中东呼吸综合征冠状病毒刺突蛋白受体结合域。
J Virol. 2014 Jun;88(12):7045-53. doi: 10.1128/JVI.00433-14. Epub 2014 Apr 9.
3
Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus.腺苷脱氨酶可作为二肽基肽酶 4 介导的中东呼吸综合征冠状病毒进入的天然拮抗剂。
J Virol. 2014 Feb;88(3):1834-8. doi: 10.1128/JVI.02935-13. Epub 2013 Nov 20.
4
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.多种中东呼吸综合征冠状病毒（MERS-CoV）的重组受体结合结构域可诱导产生针对不同人类和骆驼MERS-CoV以及抗体逃逸突变体的交叉中和抗体。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01651-16. Print 2017 Jan 1.
5
Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.韩国传播的中东呼吸综合征冠状病毒刺突蛋白突变增加了对抗体介导的中和作用的抵抗力。
J Virol. 2019 Jan 4;93(2). doi: 10.1128/JVI.01381-18. Print 2019 Jan 15.
6
Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak.韩国疫情期间对人CD26亲和力降低的中东呼吸综合征冠状病毒突变株的传播
mBio. 2016 Mar 1;7(2):e00019. doi: 10.1128/mBio.00019-16.
7
Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.一种针对中东呼吸综合征冠状病毒前融合稳定刺突蛋白的 B 细胞产生的人源单克隆抗体的鉴定。
PLoS One. 2020 May 8;15(5):e0232757. doi: 10.1371/journal.pone.0232757. eCollection 2020.
8
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.一种强效人源单克隆抗体对中东呼吸综合征冠状病毒的预防及暴露后疗效
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8. doi: 10.1073/pnas.1510199112. Epub 2015 Jul 27.
9
Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus.二肽基肽酶 4 多态性降低中东呼吸综合征冠状病毒的宿主细胞进入。
Emerg Microbes Infect. 2020 Jan 21;9(1):155-168. doi: 10.1080/22221751.2020.1713705. eCollection 2020.
10
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.抗体依赖增强作用促进冠状病毒进入的分子机制。
J Virol. 2020 Feb 14;94(5). doi: 10.1128/JVI.02015-19.

引用本文的文献

1
Modulatory Effects of the Recombinant Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike S1 Subunit Protein on the Phenotype of Camel Monocyte-Derived Macrophages.重组中东呼吸综合征冠状病毒（MERS-CoV）刺突S1亚基蛋白对骆驼单核细胞衍生巨噬细胞表型的调节作用
Biology (Basel). 2025 Mar 13;14(3):292. doi: 10.3390/biology14030292.
2
Cell-targeted vaccines: implications for adaptive immunity.细胞靶向疫苗：对适应性免疫的影响。
Front Immunol. 2023 Aug 16;14:1221008. doi: 10.3389/fimmu.2023.1221008. eCollection 2023.
3
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.二肽基肽酶-4抑制剂作为糖尿病COVID-19患者的救星。
Future Virol. 2023 Mar. doi: 10.2217/fvl-2022-0112. Epub 2023 Apr 11.
4
SARS-CoV-2 cell entry beyond the ACE2 receptor.SARS-CoV-2 细胞进入 ACE2 受体以外的途径。
Mol Biol Rep. 2022 Nov;49(11):10715-10727. doi: 10.1007/s11033-022-07700-x. Epub 2022 Jun 26.
5
Nanomedicine to deliver biological macromolecules for treating COVID-19.纳米医学递送生物大分子治疗 COVID-19。
Vaccine. 2022 Jun 23;40(29):3931-3941. doi: 10.1016/j.vaccine.2022.05.068. Epub 2022 May 30.
6
Coronavirus Entry Inhibitors.冠状病毒进入抑制剂
Adv Exp Med Biol. 2022;1366:101-121. doi: 10.1007/978-981-16-8702-0_7.
7
Sequence determinants of human-cell entry identified in ACE2-independent bat sarbecoviruses: A combined laboratory and computational network science approach.在不依赖 ACE2 的蝙蝠沙贝病毒中鉴定的人类细胞进入的序列决定因素：一种结合实验室和计算网络科学方法。
EBioMedicine. 2022 May;79:103990. doi: 10.1016/j.ebiom.2022.103990. Epub 2022 Apr 8.
8
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.二肽基肽酶4（DPP4）及DPP4抑制剂在不同肺部疾病中的作用：新证据
Front Pharmacol. 2021 Dec 9;12:731453. doi: 10.3389/fphar.2021.731453. eCollection 2021.
9
A Comprehensive View on the Host Factors and Viral Proteins Associated With Porcine Epidemic Diarrhea Virus Infection.关于与猪流行性腹泻病毒感染相关的宿主因素和病毒蛋白的综合观点
Front Microbiol. 2021 Dec 7;12:762358. doi: 10.3389/fmicb.2021.762358. eCollection 2021.
10
SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19.严重急性呼吸综合征冠状病毒2与糖尿病：二肽基肽酶4抑制剂对确诊新冠肺炎的糖尿病患者的潜在治疗作用
Metabol Open. 2021 Dec;12:100134. doi: 10.1016/j.metop.2021.100134. Epub 2021 Oct 13.

本文引用的文献

1
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.用干扰素-α2b 和利巴韦林治疗可改善 MERS-CoV 感染恒河猴的预后。
Nat Med. 2013 Oct;19(10):1313-7. doi: 10.1038/nm.3362. Epub 2013 Sep 8.
2
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4.MERS-CoV 刺突受体结合域与人受体 DPP4 复合物的结构。
Cell Res. 2013 Aug;23(8):986-93. doi: 10.1038/cr.2013.92. Epub 2013 Jul 9.
3
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26.新型人类冠状病毒 MERS-CoV 与其受体 CD26 结合的分子基础。
Nature. 2013 Aug 8;500(7461):227-31. doi: 10.1038/nature12328. Epub 2013 Jul 7.
4
Middle East Respiratory Syndrome coronavirus (MERS CoV): Update 2013.中东呼吸综合征冠状病毒（MERS-CoV）：2013 年更新。
Curr Infect Dis Rep. 2013 Aug;15(4):295-8. doi: 10.1007/s11908-013-0344-2.
5
The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.新型中东呼吸综合征冠状病毒的受体结合域位于刺突蛋白的 231 个残基区域，该区域能有效地引发中和抗体。
J Virol. 2013 Aug;87(16):9379-83. doi: 10.1128/JVI.01277-13. Epub 2013 Jun 19.
6
Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection.中东呼吸综合征冠状病毒感染病例的临床特征和病毒学分析。
Lancet Infect Dis. 2013 Sep;13(9):745-51. doi: 10.1016/S1473-3099(13)70154-3. Epub 2013 Jun 17.
7
Update: Severe respiratory illness associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)--worldwide, 2012-2013.更新：与中东呼吸综合征冠状病毒（MERS-CoV）相关的严重呼吸道疾病-全球，2012-2013 年。
MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):480-3.
8
Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission.两例中东呼吸综合征冠状病毒感染的临床特征和病毒学诊断：一起医院感染传播的报告。
Lancet. 2013 Jun 29;381(9885):2265-72. doi: 10.1016/S0140-6736(13)60982-4. Epub 2013 May 30.
9
Family cluster of Middle East respiratory syndrome coronavirus infections.家庭聚集性中东呼吸综合征冠状病毒感染。
N Engl J Med. 2013 Jun 27;368(26):2487-94. doi: 10.1056/NEJMoa1303729. Epub 2013 May 29.
10
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.中东呼吸综合征冠状病毒（MERS-CoV）：冠状病毒研究小组声明
J Virol. 2013 Jul;87(14):7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15.

抗 CD26 单克隆抗体抑制中东呼吸综合征冠状病毒感染。

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.

机构信息

Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan.

出版信息

J Virol. 2013 Dec;87(24):13892-9. doi: 10.1128/JVI.02448-13. Epub 2013 Sep 25.

DOI:10.1128/JVI.02448-13
PMID:24067970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3838260/
Abstract

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

摘要

我们使用不同的抗 CD26 单克隆抗体 (mAb) 克隆鉴定了与中东呼吸综合征冠状病毒 (MERS-CoV) 结合相关的 CD26 结构域。一种名为 2F9 的克隆几乎完全抑制了病毒进入。人源化抗 CD26 mAb YS110 也显著抑制了感染。这些发现表明 2F9 和 YS110 都是 MERS-CoV 感染的潜在治疗药物。特别是 YS110，是作为 MERS 治疗方法立即进行测试的候选药物。